Nathanael Gray
Nathanael Gray
Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School
Verified email at
Cited by
Cited by
Targeting cancer with small molecule kinase inhibitors
J Zhang, PL Yang, NS Gray
Nature reviews cancer 9 (1), 28-39, 2009
Systematic identification of genomic markers of drug sensitivity in cancer cells
MJ Garnett, EJ Edelman, SJ Heidorn, CD Greenman, A Dastur, KW Lau, ...
Nature 483 (7391), 570-575, 2012
A next generation connectivity map: L1000 platform and the first 1,000,000 profiles
A Subramanian, R Narayan, SM Corsello, DD Peck, TE Natoli, X Lu, ...
Cell 171 (6), 1437-1452. e17, 2017
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1
CC Thoreen, SA Kang, JW Chang, Q Liu, J Zhang, Y Gao, LJ Reichling, ...
Journal of Biological Chemistry 284 (12), 8023-8032, 2009
A landscape of pharmacogenomic interactions in cancer
F Iorio, TA Knijnenburg, DJ Vis, GR Bignell, MP Menden, M Schubert, ...
Cell 166 (3), 740-754, 2016
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival
TR Peterson, M Laplante, CC Thoreen, Y Sancak, SA Kang, WM Kuehl, ...
Cell 137 (5), 873-886, 2009
A unifying model for mTORC1-mediated regulation of mRNA translation
CC Thoreen, L Chantranupong, HR Keys, T Wang, NS Gray, DM Sabatini
Nature 485 (7396), 109-113, 2012
Rational design of inhibitors that bind to inactive kinase conformations
Y Liu, NS Gray
Nature chemical biology 2 (7), 358-364, 2006
A chemical switch for inhibitor-sensitive alleles of any protein kinase
AC Bishop, JA Ubersax, DT Petsch, DP Matheos, NS Gray, J Blethrow, ...
nature 407 (6802), 395-401, 2000
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
JP Koivunen, C Mermel, K Zejnullahu, C Murphy, E Lifshits, AJ Holmes, ...
Clinical cancer research 14 (13), 4275-4283, 2008
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling
PP Hsu, SA Kang, J Rameseder, Y Zhang, KA Ottina, D Lim, TR Peterson, ...
science 332 (6035), 1317-1322, 2011
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
W Zhou, D Ercan, L Chen, CH Yun, D Li, M Capelletti, AB Cortot, ...
Nature 462 (7276), 1070-1074, 2009
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
NS Gray, L Wodicka, AMWH Thunnissen, TC Norman, S Kwon, ...
Science 281 (5376), 533-538, 1998
Activating mutations in ALK provide a therapeutic target in neuroblastoma
RE George, T Sanda, M Hanna, S Fröhling, WL Ii, J Zhang, Y Ahn, ...
Nature 455 (7215), 975-978, 2008
Systematic identification of culture conditions for induction and maintenance of naive human pluripotency
TW Theunissen, BE Powell, H Wang, M Mitalipova, DA Faddah, J Reddy, ...
Cell stem cell 15 (4), 471-487, 2014
The promise and peril of chemical probes
CH Arrowsmith, JE Audia, C Austin, J Baell, J Bennett, J Blagg, C Bountra, ...
Nature chemical biology 11 (8), 536-541, 2015
YY1 is a structural regulator of enhancer-promoter loops
AS Weintraub, CH Li, AV Zamudio, AA Sigova, NM Hannett, DS Day, ...
Cell 171 (7), 1573-1588. e28, 2017
Kinase inhibitors: the road ahead
FM Ferguson, NS Gray
Nature reviews Drug discovery 17 (5), 353-377, 2018
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
N Kwiatkowski, T Zhang, PB Rahl, BJ Abraham, J Reddy, SB Ficarro, ...
Nature 511 (7511), 616-620, 2014
MEK1 mutations confer resistance to MEK and B-RAF inhibition
CM Emery, KG Vijayendran, MC Zipser, AM Sawyer, L Niu, JJ Kim, ...
Proceedings of the National Academy of Sciences 106 (48), 20411-20416, 2009
The system can't perform the operation now. Try again later.
Articles 1–20